Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab

Mamesaya, Nobuaki; Kenmotsu, Hirotsugu; Takahashi, Toshiaki
December 2017
Investigational New Drugs;Dec2017, Vol. 35 Issue 6, p839
Academic Journal
No abstract available.


Related Articles

  • Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Kawase, Shigeo; Hattori, Noboru; Ishikawa, Nobuhisa; Horimasu, Yasushi; Fujitaka, Kazunori; Furonaka, Osamu; Isobe, Takeshi; Miyoshi, Seigo; Hamada, Hironobu; Yamane, Takashi; Yokoyama, Akihito; Kohno, Nobuoki // Respiratory Research;Jul2011, Vol. 12 Issue 7, p1 

    Background: A high incidence of interstitial lung disease (ILD) has been reported in patients with advanced non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), particularly in Japanese populations. A previous...

  • Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients. Nyberg, Fredrik; Ogiwara, Atsushi; Harbron, Chris G.; Kawakami, Takao; Nagasaka, Keiko; Takami, Sachiko; Wada, Kazuya; Tu, Hsiao-Kun; Otsuji, Makiko; Kyono, Yutaka; Dobashi, Tae; Komatsu, Yasuhiko; Kihara, Makoto; Akimoto, Shingo; Peers, Ian S.; South, Marie C.; Higenbottam, Tim; Fukuoka, Masahiro; Nakata, Koichiro; Ohe, Yuichiro // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Interstitial lung disease (ILD) events have been reported in Japanese non-small-cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors. We investigated proteomic biomarkers for mechanistic insights and improved prediction of ILD. Blood plasma was collected from 43...

  • Role of Tyrosine Kinase Inhibitors in Lung Cancer. Ansari, J.; Palmer, D. H.; Rea, D. W.; Hussain, S. A. // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 5, p569 

    Protein tyrosine kinases are enzymes which catalyze the phosphorylation of tyrosine residues and activate a downstream cascade of cellular signalling pathways which regulate cell proliferation, differentiation and apoptosis and a wide variety of cellular functions. Clinical developments over the...

  • Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer. Tao JIANG; Caicun ZHOU // Chinese Journal of Lung Cancer;4/20/2015, Vol. 18 Issue 4, p240 

    Molecular targeted therapy has become more and more important in the treatment of non-small cell lung cancer (NSCLC). HGF/c-MET plays the pivotal role in the growth, development and tolerance to epidermal growth factor receptor tyrosine kinase inhibitor of NSCLC. Moreover it has become another...

  • Gefitinib in Patients of Asian Ethnicity or Never Smokers. Toschi, Luca; Cappuzzo, Federico // Asia Pacific Journal of Oncology & Hematology;2009, Vol. 1 Issue 1, p45 

    Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been proven to be active in selected patients with advanced non-small cell lung cancer (NSCLC), including women, patients with adenocarcinomas, Asians and never smokers. The biological reasons underlying this...

  • The Role of Pemetrexed in Lung Adenocarcinoma, Mixed Subtype with Bronchioloalveolar Carcinoma Features. Duruisseaux, Micha�l; Cadranel, Jacques; P�rol, Maurice; Arpin, Dominique // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p74 

    No abstract available.

  • Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer. Tianhong Li; Lara Jr., Primo N.; Mack, Philip C.; Perez-Soler, Roman; Gandara, David R. // Current Drug Targets;Jan2010, Vol. 11 Issue 1, p85 

    No abstract available.

  • Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Sequist, Lecia V. // Oncologist;Mar2007, Vol. 12 Issue 3, p325 

    Inhibiting epidermal growth factor receptor (EGFR) signaling has proven to be an effective strategy for treating non-small cell lung cancer (NSCLC) patients and the first generation of agents developed for this purpose, gefitinib and erlotinib, stimulated a unique escalation in both biologic and...

  • Impact of EGFR mutations on treatment of non-small cell lung cancer. Johnson, Bruce E.; Jackman, David; Jänne, Pasi A. // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p5 

    Somatic mutations in the epidermal growth factor receptor ( EGFR) have been identified in advanced non-small cell lung cancer (NSCLC) patients who achieve dramatic clinical and radiographic responses to treatment with the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib....

  • Current Roles and Future Perspectives of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer. Lin, Zhong-Zhe; Yang, Chih-Hsin // European Journal of Clinical & Medical Oncology;2010, Vol. 2 Issue 3, p1 

    Clinical application of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib has revolutionized systemic treatment for advanced non-small-cell lung cancer (NSCLC) patients. The therapeutic efficacy of EGFR-TKI monotherapy as a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics